CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $327,625 | +2.2% | 7,218 | +26.4% | 0.01% | 0.0% |
| Q2 2023 | $320,616 | -40.0% | 5,711 | -51.6% | 0.01% | -36.4% |
| Q1 2023 | $533,940 | +10.3% | 11,805 | -0.8% | 0.01% | +10.0% |
| Q4 2022 | $483,938 | -67.0% | 11,905 | -46.9% | 0.01% | -67.7% |
| Q3 2022 | $1,465,000 | +0.9% | 22,414 | -6.2% | 0.03% | +10.7% |
| Q2 2022 | $1,452,000 | -16.4% | 23,895 | -13.6% | 0.03% | +3.7% |
| Q1 2022 | $1,737,000 | -38.0% | 27,670 | -25.2% | 0.03% | -32.5% |
| Q4 2021 | $2,802,000 | -33.8% | 36,977 | -2.2% | 0.04% | -37.5% |
| Q3 2021 | $4,230,000 | -23.4% | 37,794 | +10.9% | 0.06% | -21.0% |
| Q2 2021 | $5,519,000 | +57.2% | 34,092 | +18.3% | 0.08% | +47.3% |
| Q1 2021 | $3,510,000 | +36.6% | 28,808 | +71.6% | 0.06% | +27.9% |
| Q4 2020 | $2,570,000 | +768.2% | 16,784 | +375.1% | 0.04% | +760.0% |
| Q3 2020 | $296,000 | +112.9% | 3,533 | +86.2% | 0.01% | +66.7% |
| Q2 2020 | $139,000 | – | 1,897 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |